Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients Feriel Fennira, MD, François Chasset, MD, Martin Soubrier, MD, PhD, Nadège Cordel, MD, Antoine Petit, MD, Camille Francès, MD Journal of the American Academy of Dermatology Volume 74, Issue 6, Pages 1248-1251 (June 2016) DOI: 10.1016/j.jaad.2016.01.054 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Before and after lenalidomide treatment (Revlimid; Celgene) in patients with cutaneous lupus erythematosus and median revised cutaneous lupus erythematosus disease area and severity index (RCLASI) for 16 patients. A, Patient 5, discoid lupus erythematosus of the hands. Evaluation at 6 months: partial response. B, Patient 8, discoid lupus erythematous on the face before treatment; the lesions are partially hidden by the thick makeup, which was difficult to remove for photography. Evaluation at 3 months: complete response. C, RCLASI changes for 16 patients (black bars) and median RCLASI improvement (red bars) before and after 3, 6, and 12 months of lenalidomide treatment. The median RCLASI was significantly reduced between baseline and month 3 from 23 (range 11-48) to 4 (0-37) (P < .001). Median RCLASIs were 1.5 (0-5) and 0 (0-6) at month 6 (n = 11 patients) and month 12 (n = 9 patient), respectively. No case of relapse defined by an increase of at least 2 points of RCLASI or a new occurrence of cutaneous lesions after complete response occurred during follow-up. Journal of the American Academy of Dermatology 2016 74, 1248-1251DOI: (10.1016/j.jaad.2016.01.054) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions